UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1014-18
Program Prior Authorization/Notification
Medication Compounds and Bulk Powders
P&T Approval Date 1/2012, 02/2013, 04/2013, 07/2013, 10/2013, 11/2013, 2/2014, 4/2014,
10/2014, 4/2015, 7/2015, 4/2016, 10/2016, 10/2017, 10/2018, 10/2019,
5/2020, 1/2021, 3/2022, 3/2023, 3/2024, 4/2025, 6/2025
Effective Date 7/1/2025
1. Background:
Compounded medications can provide a unique route of delivery for certain patient-
specific conditions and administration requirements. Compounded medications should
be produced for a single individual and not produced on a large scale. A dollar threshold
may be used to identify compounds which require Notification and must meet the criteria
below in order to be covered. Drugs included in the compound must be a covered
product.
Claims for patients under the age of 6 will process automatically for First-Lansoprazole,
First-Omeprazole, and Omeprazole + Syrspend SF compounding kits.
2. Coverage Criteriaa:
A. Authorization for compounds* and bulk powders will be approved based on all of
the following criteria (includes bulk powders requested as a single ingredient such as
bulk powder formulations of cholestyramine or nystatin when the powder
formulation requested is not the commercially available FDA approved product):
1. The requested drug component is a covered medication
-AND-
2. The requested drug component is to be administered for an FDA-approved
indication
-AND-
3. If a drug included in the compound requires prior authorization and/or step
therapy, all drug specific clinical criteria must also be met
-AND-
4. If the drug component is no longer available commercially it must not have been
withdrawn for safety reasons
-AND-
© 2025 UnitedHealthcare Services, Inc.
5. One of the following:
a. A unique vehicle is required
-OR-
b. A unique dosage form is required for a commercially available product due
to patient’s age, weight or inability to take a solid dosage form.
-OR-
c. A unique formulation is required for a commercially available product due to
an allergy or intolerance to an inactive ingredient in the commercially
available product
-OR-
d. There is a shortage of the commercially available product per the FDA Drug
Shortage database or the ASHP Current Drug Shortages tracking log
-AND-
6. Coverage for compounds and bulk powders will NOT be approved for any of the
following:
a. Requested compound contains any of the following ingredients which are
available as over-the-counter products:
(1) Cetyl Myristoleate
(2) Coenzyme Q10
(3) Methylcobalamin
(4) Hyaluronic Acid
(5) Nicotinamide
(6) Methyltetrahydrofolate
(7) Ibuprofen
(8) Lipoic acid
(9) Beta Glucan
(10) Ubiquinol
(11) Chrysin
(12) Glutathione
(13) Lactobacillus
(14) Vitamin E
(15) Ascorbic Acid
(16) Melatonin
(17) Pyridoxal-5-Phosphate (Vitamin B6)
(18) Loperamide
(19) Dextromethorphan
(20) Dehydroepiandrosterone
(21) Pregnenolone
(22) Biotin
© 2025 UnitedHealthcare Services, Inc.
(23) L-Glutamine
(24) Serotonin
(25) Aloe vera
(26) Sodium butyrate
(27) L-Isoleucine
(28) Vitamin D3
(29) Ginseng
(30) Phosphatidylserine
(31) Resveratrol
(32) Methionine
(33) Naproxen
(34) Carnosine L
(35) Arnica LG
-OR-
b. For topical compound preparations (e.g. creams, ointments, lotions or gels to
be applied to the skin for transdermal, transcutaneous or any other topical
route), requested compound contains any FDA approved ingredient that is
not FDA approved for TOPICAL use, including but NOT LIMITED TO the
following:
(1) Ketamine
(2) Gabapentin
(3) Flurbiprofen (topical ophthalmic use not included)
(4) Ketoprofen
(5) Morphine
(6) Nabumetone
(7) Oxycodone
(8) Cyclobenzaprine
(9) Baclofen
(10) Tramadol
(11) Hydrocodone
(12) Meloxicam
(13) Amitriptyline
(14) Pentoxifylline
(15) Orphenadrine
(16) Piroxicam
(17) Levocetirizine
(18) Amantadine
(19) Oxytocin
(20) Sumatriptan
(21) Chorionic gonadotropin (human)
(22) Clomipramine
(23) Dexamethasone
(24) Hydromorphone
(25) Methadone
(26) Papaverine
(27) Mefenamic acid
(28) Promethazine
© 2025 UnitedHealthcare Services, Inc.
(29) Succimer DMSA
(30) Tizanidine
(31) Apomorphine
(32) Carbamazepine
(33) Ketorolac
(34) Dimercaptopropane-sulfonate
(35) Dimercaptosuccinic acid
(36) Duloxetine
(37) Fluoxetine
(38) Bromfenac (topical ophthalmic use not included)
(39) Nepafenac (topical ophthalmic use not included)
-OR-
c. Requested compound contains topical fluticasone. Topical fluticasone will
NOT be approved unless:
(1) Topical fluticasone is intended to treat a dermatologic condition. Scar
treatments are considered cosmetic and will not be covered (refer to
criteria “e” below).
-AND-
(2) Patient has a contraindication to all commercially available topically
fluticasone formulations
-OR-
d. Requested compound contains leuprolide when prescribed for off-label use
(refer to leuprolide criteria)
-OR-
e. Requested compound is for cosmetic use or contains any of the following
ingredients when used for cosmetic purposes:
(1) Hydroquinone
(2) Acetyl hexapeptide-8
(3) Tocopheryl Acid Succinate
(4) PracaSil TM-Plus
(5) Chrysaderm Day Cream
(6) Chrysaderm Night Cream
(7) PCCA Spira-Wash
(8) Lipopen Ultra
(9) Versapro
(10) Fluticasone
(11) Mometasone
(12) Halobetasol
(13) Betamethasone
(14) Clobetasol
(15) Triamcinolone
© 2025 UnitedHealthcare Services, Inc.
(16) Minoxidil
(17) Tretinoin
(18) Dexamethasone
(19) Spironolactone
(20) Cycloserine
(21) Tamoxifen
(22) Sermorelin
(23) Mederma Cream
(24) PCCA Cosmetic HRT Base
(25) Sanare Scar Therapy Cream
(26) Scarcin Cream
(27) Apothederm
(28) Stera Cream
(29) Copasil
(30) Collagenase
(31) Arbutin Alpha
(32) Nourisil
(33) Freedom Cepapro
(34) Freedom Silomac Andydrous
(35) Retinaldehyde
(36) Apothederm
-OR-
f. Requested compound contains cholestyramine when prescribed for an off-
label use. (FDA labeled uses include: hypercholesterolemia, coronary artery
atherosclerosis, and pruritus associated with biliary obstruction)
-OR-
g. Requested compound contains nystatin when prescribed for an off-label use.
-OR-
h. Requested compound contains any of the following ingredients which are on
the FDA’s Do Not Compound List:
(1) 3,3′,4′,5-tetrachlorosalicylanilide
(2) Adenosine phosphate
(3) Adrenal cortex
(4) Alatrofloxacin mesylate
(5) Aminopyrine
(6) Astemizole
(7) Azaribine
(8) Benoxaprofen
(9) Bithionol
(10) Camphorated oil
(11) Carbetapentane citrate
(12) Casein, iodinated
(13) Cerivastatin sodium
© 2025 UnitedHealthcare Services, Inc.
(14) Chlormadinone acetate
(15) Chloroform
(16) Cisapride
(17) Exfenfluramine hydrochloride
(18) Diamthazole dihydrochloride
(19) Dibromsalan
(20) Dihydrostreptomycin sulfate
(21) Dipyrone
(22) Encainide hydrochloride
(23) Etretinate
(24) Fenfluramine hydrochloride
(25) Flosequinan
(26) Glycerol, iodinated
(27) Grepafloxacin
(28) Mepazine
(29) Metabromsalan
(30) Methapyrilene
(31) Methopholine
(32) Methoxyflurane
(33) Mibefradil dihydrochloride
(34) Nomifensine maleate
(35) Novobiocin sodium
(36) Oxyphenisatin acetate
(37) Oxyphenisatin
(38) Pemoline
(39) Pergolide mesylate
(40) Phenacetin
(41) Phenformin hydrochloride
(42) Phenylpropanolamine
(43) Pipamazine
(44) Potassium arsenite
(45) Propoxyphene
(46) Rapacuronium bromide
(47) Rofecoxib
(48) Sibutramine hydrochloride
(49) Sparteine sulfate
(50) Sulfadimethoxine
(51) Sweet spirits of nitre
(52) Tegaserod maleate
(53) Temafloxacin hydrochloride
(54) Terfenadine
(55) Ticrynafen
(56) Tribromsalan
(57) Trichloroethane
(58) Troglitazone
(59) Trovafloxacin mesylate:
(60) Urethane
(61) Valdecoxib
(62) Zomepirac sodium
© 2025 UnitedHealthcare Services, Inc.
Authorization will be issued for 12 months
B. Authorization for the compounding kits First-Lansoprazole ,First-Omeprazole
and Omeprazole + Syrspend SF will be approved based on all of the following
criteria:
1. The requested drug component in the compounding kit is to be administered for
an FDA-approved indication
-AND-
2. One of the following:
a. A unique dosage form is required for a covered commercially available
product due to the patient’s age, weight or inability to take a solid dosage
form.
-OR-
b. A unique formulation is required for a covered commercially available
product due to an allergy or intolerance to an inactive ingredient in the
commercially available product.
Authorization will be issued for 12 months
C. Authorization for compounded oral budesonide for the treatment of eosinophilic
esophagitis will be approved based on the following criteria (all other indications
refer to general criteria in Section A):
1. Compounded oral budesonide is requested for the treatment of eosinophilic
esophagitis
Authorization will be issued for 12 months
a For Kentucky, requests for therapeutic food, formulas, supplements, low-protein modified food
products, vitamins, nutritional supplements and amino acid-based elemental medical formula
for the treatment of inborn errors of metabolism, genetic conditions, mitochondrial disease,
food protein allergies, food protein-induced enterocolitis syndrome, eosinophilic disorders, or
short-bowel syndrome may be approved through review by UnitedHealthcare Pharmacy.
Please note there is a plan year cap of twenty five thousand dollars ($25,000) for therapeutic
foods, formulas and supplements, and a separate cap for each plan year of four thousand dollars
($4,000) on low-protein modified foods. Each cap shall be subject to annual inflation
adjustments based on the consumer price index.
* For appeals only: An injectable product which is intended to be used for a route of
administration typically covered on the pharmacy benefit (e.g. topical, intranasal, oral) will be
considered a compound for the purposes of this clinical pharmacy program.
3. Additional Clinical Rules:
• Supply limits, Step Therapy and/or Prior Authorization may be in place.
© 2025 UnitedHealthcare Services, Inc.
4. References:
1. Food and Drug Administration (2014, July 02). Additions and Modifications to the
List of Drug Products That Have Been Withdrawn or Removed From the Market for
Reasons of Safety and Effectiveness. Retrieved from
https://www.federalregister.gov/d/2014-15371
2. FDA Drug Shortages. Current and Resolved Drug Shortages and Discontinuations
Reported to the FDA. Available at: https://www.fda.gov/drugs/drug-safety-and-
availability/drug-shortages3. ASHP Current Drug Shortages. Available at:
https://www.ashp.org/Drug-Shortages/Current-Shortages
Program Prior Authorization/Notification - Compounds and Bulk Powders
Change Control
Date Change
7/2013 Topical use section updated to include all medications that are not FDA
approved for topical use. Reformatted to standard.
10/2013 Added the following to the list of compound ingredients that are not
covered: ibuprofen, lipoic acid, beta glucan, ubiquinol, chrysin,
glutathione, lactobacillus, vitamin E, ascorbic acid, melatonin,
meloxicam, amitriptyline, pentoxifylline, orphenadrine, piroxicam,
acetyl hexapeptide-8, tocopheryl acid succinate, PracaSil TM-Plus,
Chrysaderm Day Cream, Chrysaderm Night Cream, PCCA Spira-Wash
and Lipopen Ultra.
11/2013 Added criteria for topical fluticasone.
2/2014 Added criteria for cholestyramine.
4/2014 Added pyridoxal-5-phosphate (Vitamin B6) and loperamide to list of
ingredients that will not be coverage as they are available OTC. Added
levocetirizine, amantadine, oxytocin, sumatriptan and chorionic
gonadotropin to list of ingredients that will not be covered for topical
use. Added Versapro to list of ingredients that will not be covered for
cosmetic use.
10/2014 Added Dextromethorphan, Dehydroepiandrosterone, Pregnenolone,
Biotin, L-Glutamine, Serotonin, Aloe vera, Sodium butyrate, L-
Isoleucine and Vitamin D3 to the list of ingredients that will not be
covered as they are available OTC. Added Clomipramine,
Dexamethasone, Hydromorphone, Methadone, Papaverine, Mefenamic
acid, Promethazine, Succimer DMSA, Tizanidine, Apomorphine,
Carbamazepine, Ketorolac, Dimercaptopropane-sulfonate and
Dimercaptosuccinic acid to the list of ingredients that will not be
covered for topical use. Added Fluticasone, Mometasone, Halobetasol,
Betamethasone, Clobetasol, Triamcinolone, Minoxidil, Tretinoin,
Dexamethasone, Spironolactone, Cycloserine, Tamoxifen and
Sermorelin to the list of ingredients that will not be covered for
cosmetic use. Removed criterion that a similar commercially available
product is not available.
4/2015 Updated criteria to reflect that if any drug ingredient of the compound
requires prior authorization and/or step therapy, that clinical criteria
must also be met. Added ginseng, phosphatidylserine and resveratrol to
© 2025 UnitedHealthcare Services, Inc.
the ingredients that will not be covered as they are available OTC.
Added Mederma Cream, PCCA Cosmetic HRT Base, Sanare Scar
Therapy Cream, and Scarcin Cream to the ingredients that will not be
covered for cosmetic use.
7/2015 Added to the criteria ingredients that should not be compounded as they
reside on the FDA’s Do Not Compound List. Clarified language
around commercially available products.
4/2016 Added criteria to allow for coverage when patient has an allergy to the
commercially available product. Added methionine and naproxen to
ingredients that will not be covered as they are available OTC. Added
Apothederm to the list of ingredients that will not be covered for
cosmetic use.
10/2016 Removed language that a unique dosage form is required and the
commercially available product is excluded. Added Kentucky state
mandate language. Added carnosine L to the ingredients that will not
be covered as they are available OTC. Added duloxetine and fluoxetine
to the ingredients that will not be covered for topical use. Added Stera
cream, Copasil, collagenase, arbutin alpha, and Nourisil to the list of
ingredients that will not be covered for cosmetic use.
10/2017 Added criteria for First-Lansoprazole and First-Omeprazole. Added
Arnica LG to the ingredients that will not be covered as they are
available OTC. Added bromfenac and nepafenac to the ingredients that
will not be covered for topical use. Added Freedom Cepapro, Silomac
Anhydrous, Retinaldehyde and Apothederm to the list of ingredients
that will not be covered for cosmetic use.
10/2018 Annual review. No changes.
10/2019 Annual review. Clarified that bulk powders are included when not
included in a compound. Added criteria for nystatin powder.
5/2020 Updated to allow coverage of a compound when there is a shortage of
the commercially available product. Clarified that compounds for
cosmetic use will not be covered.
1/2021 Added Omeprazole Syrspend + SF compounding kit to criteria.
Removed note that First Omeprazole and First Lansoprazole are
typically excluded from coverage.
3/2022 Added note that injectable products intended for use with a route of
administration typically covered under the pharmacy benefit may be
reviewed with these criteria. Updated requirement that a unique vehicle
is needed and removed specifically for a topical product.
3/2023 Annual review. No changes.
3/2024 Annual review. No changes.
4/2025 Annual review. Updated references.
6/2025 Oral budesonide added to criteria.
© 2025 UnitedHealthcare Services, Inc.